# Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

> **NCT05890235** · PHASE4 · COMPLETED · sponsor: **Xintian Pharmaceutical** · enrollment: 323 (actual)

## Conditions studied

- Chronic Prostatitis

## Interventions

- **DRUG:** Ningmitai Capsule
- **DRUG:** Tamsulosin Hydrochloride

## Key facts

- **NCT ID:** NCT05890235
- **Lead sponsor:** Xintian Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-16
- **Primary completion:** 2022-07-10
- **Final completion:** 2022-07-10
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05890235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05890235, "Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05890235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*